Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 3
2005 1
2006 1
2007 5
2008 1
2009 1
2010 2
2011 1
2012 6
2013 4
2014 6
2015 5
2016 12
2017 13
2018 12
2019 16
2020 23
2021 38
2022 30
2023 19
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Treatment patterns and prognosis in patients with Bacillus Calmette-Guérin-exposed high-risk non-muscle invasive bladder cancer: a real-world data analysis.
Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Okajima E, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Nishimura N, et al. Among authors: kojima t. World J Urol. 2024 Mar 21;42(1):185. doi: 10.1007/s00345-024-04834-4. World J Urol. 2024. PMID: 38512511
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H, Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H, Fujimoto K; Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Miyake M, et al. Among authors: kojima t. BJUI Compass. 2023 Nov 3;5(2):269-280. doi: 10.1002/bco2.305. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371197 Free PMC article.
Deceptive orbital confinement at edges and pores of carbon-based 1D and 2D nanoarchitectures.
Piquero-Zulaica I, Corral-Rascón E, Diaz de Cerio X, Riss A, Yang B, Garcia-Lekue A, Kher-Elden MA, Abd El-Fattah ZM, Nobusue S, Kojima T, Seufert K, Sakaguchi H, Auwärter W, Barth JV. Piquero-Zulaica I, et al. Among authors: kojima t. Nat Commun. 2024 Feb 5;15(1):1062. doi: 10.1038/s41467-024-45138-w. Nat Commun. 2024. PMID: 38316774 Free PMC article.
Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Nishiyama N, Kimura T, Yamashita S, Kitamura H, Miyake H; Japanese Urological Oncology Group. Matsushita Y, et al. Among authors: kojima t. Int J Urol. 2024 Jan 19. doi: 10.1111/iju.15396. Online ahead of print. Int J Urol. 2024. PMID: 38240169
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Sazuka T, et al. Among authors: kojima t. Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4. Sci Rep. 2023. PMID: 37996622 Free PMC article.
178 results